



## New York City COVID-19 Cases Caused by SARS-CoV-2 Variants Report (5.25.2021)

Data pulled 5/25/21 from GISAID; variants available in GISAID for NYC residents, cumulative\*

| Variants of concern that are being monitored by CDC   |  |                    |
|---|--|--------------------|
| B.1.1.7   |  | 4,721              |
| B.1.351   |  | 38                 |
| B.1.429   |  | 254                |
| B.1.427   |  | 141 <sup>^</sup>   |
| P.1   |  | 291                |
| Other variants of interest being monitored by CDC   |  |                    |
| B.1.526/B.1.526.2   |  | 7,242 <sup>^</sup> |
| B.1.526.1   |  | 1,476              |
| B.1.525   |  | 54                 |
| B.1.617   |  | 0                  |
| B.1.617.1   |  | 3 <sup>^</sup>     |
| B.1.617.2   |  | 62                 |
| B.1.617.3   |  | 0                  |
| P.2   |  | 12                 |
| Number of <a href="#">genome sequences</a> from specimens from NYC residents in GISAID, cumulative* |  | 20,618             |

\* [GISAID](#) is a global science repository for open-access to genomic data of SARS-CoV2. Cumulative refers to January 2021 – present. All sequences noted as “available in GISAID” have passed critical quality control checks and are publicly available.

<sup>^</sup>GISAID updated lineage assignments that resulted in the reclassification of some previously assigned as B.1.427, B.1.526/B.1.526.2, and B.1.617.1 to other lineages

For national figures, see the CDC’s US COVID-19 Cases Caused by Variants: <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html>. For additional SARS-CoV-2 variant classifications and definitions, see <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html>

### Trends based on a sample of specimens submitted to Pandemic Response Lab, as of 5/23

| Specimen collection date, week | Total specimens sequenced by PRL | B.1.1.7 (N, %) | B.1.351 (N, %) | B.1.429 (N, %) | B.1.427 (N, %) | P.1 (N, %) | B.1.526 (N, %)* |                 | B.1.526.1 (N, %) | B.1.525 (N, %) | B.1.617 (N, %) | B.1.617.1 (N, %) | B.1.617.2 (N, %) | B.1.617.3 (N, %) | P.2 (N, %) |
|--------------------------------|----------------------------------|----------------|----------------|----------------|----------------|------------|-----------------|-----------------|------------------|----------------|----------------|------------------|------------------|------------------|------------|
|                                |                                  |                |                |                |                |            | S:E484K+ (N, %) | S:E484K- (N, %) |                  |                |                |                  |                  |                  |            |
| Feb 8 - 14                     | 734                              | 52 (7.1%)      | 0 (0%)         | 9 (1.2%)       | 4 (0.5%)       | 0 (0%)     | 111 (15.1%)     | 103 (14%)       | 0 (0%)           | 1 (0.1%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 3 (0.4%)   |
| Feb 15 - 21                    | 826                              | 69 (8.4%)      | 2 (0.2%)       | 5 (0.6%)       | 8 (1.0%)       | 0 (0%)     | 133 (16.1%)     | 121 (14.6%)     | 0 (0%)           | 1 (0.1%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| Feb 22 - 28                    | 990                              | 118 (11.9%)    | 0 (0%)         | 12 (1.2%)      | 4 (0.4%)       | 0 (0%)     | 207 (20.9%)     | 178 (18%)       | 0 (0%)           | 4 (0.4%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 2 (0.2%)   |
| March 1 - 7                    | 715                              | 125 (17.5%)    | 0 (0%)         | 14 (2.0%)      | 3 (0.4%)       | 0 (0%)     | 168 (23.5%)     | 153 (21.4%)     | 0 (0%)           | 1 (0.1%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| March 8 - 14                   | 1481                             | 141 (9.5%)     | 0 (0%)         | 13 (0.9%)      | 2 (0.1%)       | 1 (0.1%)   | 227 (15.3%)     | 254 (17.2%)     | 0 (0%)           | 0 (0%)         | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| March 15 - 21                  | 698                              | 183 (26.2%)    | 2 (0.3%)       | 8 (1.1%)       | 5 (0.7%)       | 4 (0.6%)   | 195 (27.9%)     | 105 (15.0%)     | 64 (9.2%)        | 2 (0.3%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| March 22 - 28                  | 1496                             | 441 (29.5%)    | 4 (0.3%)       | 17 (1.1%)      | 5 (0.3%)       | 19 (1.3%)  | 381 (25.5%)     | 295 (19.7%)     | 146 (9.8%)       | 3 (0.2%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| March 29 - April 4             | 1195                             | 425 (35.6%)    | 4 (0.3%)       | 6 (0.5%)       | 9 (0.8%)       | 15 (1.3%)  | 305 (25.5%)     | 201 (16.8%)     | 104 (8.7%)       | 6 (0.5%)       | 0 (0%)         | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| April 5 - 11                   | 1831                             | 665 (36.3%)    | 4 (0.2%)       | 7 (0.4%)       | 7 (0.4%)       | 47 (2.6%)  | 463 (25.3%)     | 276 (15.1%)     | 167 (9.1%)       | 5 (0.3%)       | 1 (0.1%)       | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| April 12 - 18                  | 1404                             | 532 (37.9%)    | 5 (0.4%)       | 11 (0.8%)      | 6 (0.4%)       | 47 (3.4%)  | 366 (26.1%)     | 196 (14.0%)     | 97 (6.9%)        | 9 (0.6%)       | 1 (0.1%)       | 0 (0%)           | 0 (0%)           | 0 (0%)           | 0 (0%)     |
| April 19-25                    | 955                              | 402 (41.5%)    | 1 (0.1%)       | 3 (0.3%)       | 9 (0.8%)       | 34 (3.6%)  | 229 (24%)       | 121 (12.7%)     | 52 (5.4%)        | 5 (0.5%)       | 0 (0%)         | 1 (0.1%)         | 3 (0.3%)         | 0 (0%)           | 0 (0%)     |
| April 26 - May 2               | 699                              | 303 (43.3%)    | 1 (0.1%)       | 2 (0.3%)       | 1 (0.1%)       | 41 (5.9%)  | 130 (18.5%)     | 87 (12.4%)      | 55 (7.9%)        | 1 (0.1%)       | 0 (0%)         | 0 (0%)           | 16 (2.3%)        | 0 (0%)           | 0 (0%)     |
| May 3 - 9                      | 414                              | 196 (47.3%)    | 5 (1.2%)       | 2 (0.5%)       | 2 (0.5%)       | 24 (5.8%)  | 56 (13.5%)      | 39 (9.4%)       | 17 (4.1%)        | 5 (1.2%)       | 0 (0%)         | 0 (0%)           | 17 (4.1%)        | 0 (0%)           | 2 (0.5%)   |
| May 10 - 16                    | 361                              | 147 (40.7%)    | 0 (0%)         | 1 (0.3%)       | 2 (0.6%)       | 18 (5%)    | 47 (13%)        | 54 (15%)        | 26 (7.2%)        | 4 (1.1%)       | 0 (0%)         | 0 (0%)           | 15 (4.2%)        | 0 (0%)           | 0 (0%)     |

\*\* Estimates are derived from a subset of specimens submitted to the New York City Pandemic Response Laboratory (PRL) for diagnostic testing and may not be completely representative of all NYC COVID cases. The rate of variants in these samples may not be generalizable to all NYC COVID infections. PRL receives specimens from New York City Health and Hospitals outpatient and inpatient facilities, including community Test & Trace Corps sites, as well as private providers. Specimens are eligible for sequence analysis if they are from a New York City resident and meet specific virologic thresholds.

+ Based on a Pangolin reassignment of lineages, the B.1.526 lineage consists of B.1.526 and B.1.526.2 as of specimen collection week March 15-21.